COMPANY

Axon Therapies

HQ: New York, NY (US office) source · axontherapies.com ↗ · New England

Location: New York, NY (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Heart Failure With Reduced Ejection Fraction Heart Failure With Preserved Ejection Fraction Greater Splanchnic Nerve Ablation Right Greater Splanchnic Nerve (GSN) ablation Ablation

3Trials (company is sponsor)

Timeline

Mar 1, 2026 Trial start Not phased (device or behavioral study): Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction source ↗
Dec 18, 2020 Trial start Not phased (device or behavioral study): Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF source ↗
Feb 1, 2020 Trial start Not phased (device or behavioral study): Endovascular GSN Ablation in Subjects With HFpEF source ↗

Upcoming milestones

Jan 10, 2028 (ESTIMATED) · Not phased · Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF · NCT04592445
Mar 1, 2028 (ESTIMATED) · Not phased · Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction · NCT07403058

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT04592445	Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF	Not phased (device or behavioral study)	Recruiting	Dec 18, 2020	Jan 10, 2028 (estimated)
NCT07403058	Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction	Not phased (device or behavioral study)	Not yet recruiting	Mar 1, 2026	Mar 1, 2028 (estimated)
NCT04287946	Endovascular GSN Ablation in Subjects With HFpEF	Not phased (device or behavioral study)	Unknown status (ClinicalTrials.gov)	Feb 1, 2020	2024-06 (estimated)